Hye-Kyung Jung
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Previous Organizations / Institutes
The organizations / institutes from the scholar's other articles in the past ten years
Research Subjects
Hye-Kyung Jung has a total of 434 co-authors. Here are the top co-authors by number of shared publications:
- Ki-Nam Shim
Department of Internal Medicine Ewha Womans University College of Medicine Seoul Korea
32 shared publications - Seong-Eun Kim
Department of Internal Medicine, College of Medicine, Ewha Womans University, Seoul, Korea
30 shared publications - Sung-Ae Jung
Department of Internal Medicine, Ewha Womans University College of Medicine, Seoul, Korea
26 shared publications Sung-Ae Jung
Department of Internal Medicine, College of Medicine, Ewha Womans University, Seoul, Republic of Korea
16 shared publicationsChung Hyun Tae
Department of Internal Medicine, College of Medicine Ewha Womans University Seoul Korea
14 shared publicationsChang Mo Moon
Department of Internal Medicine, College of Medicine, Ewha Womans University, Seoul, Korea
12 shared publications
Latest Publications
- Open Access
- 2 October 2026
- Published by Wiley in Alimentary Pharmacology & Therapeutics
Letter: P‐CAB Versus PPI for Antithrombotic Gastroprotection: The Importance of Longitudinal Treatment Dynamics—Authors' Reply
- 2 October 2026
- Published by Wiley in Alimentary Pharmacology & Therapeutics
Open AccessLetter: P‐CAB Versus PPI for Antithrombotic Gastroprotection: The Importance of Longitudinal Treatment Dynamics—Authors' Reply
- Open Access
- 10 September 2026
- Published by Korean College of Helicobacter and Upper Gastrointestinal Research in The Korean Journal of Helicobacter and Upper Gastrointestinal Research
- Vol. 26 (3) , 345-350
An Intraductal Papillary Mucinous Neoplasm–Like Lesion Manifesting as a Duodenal Polyp: A Rare Case Report
Intraductal papillary mucinous neoplasms (IPMNs) typically originate within the pancreatic ductal system. However, the occurrence of an IPMN–like mucinous neoplasm outside the pancreas, presenting as an isolated duodenal polyp, is extremely rare. An asymptomatic 64-year-old woman underwent routine screening endoscopy, which revealed a 25-mm Yamada type IV pedunculated polypoid lesion in the second portion of the duodenum. En bloc endoscopic mucosal resection was performed without procedural complications, although histological evaluation revealed focal involvement of the deep resection margin. Histopathological examination demonstrated a mucinous neoplasm confined within the duodenal submucosa with papillary architecture and low-grade dysplasia, which was designated as a duodenal IPMN–like lesion. Post-procedural CT showed no concurrent pancreatic involvement, and endoscopy at 6 months demonstrated a stable post-resection scar without local recurrence. Extended follow-up with dedicated pancreatic imaging is ongoing. This case report describes a particularly uncommon duodenal IPMN–like lesion presenting as a polyp. This case highlights the importance of careful histological evaluation and the inclusion of pancreaticobiliary-type neoplasms in the differential diagnosis of atypical periampullary lesions, along with long-term surveillance.
- 10 September 2026
- Published by Korean College of Helicobacter and Upper Gastrointestinal Research in The Korean Journal of Helicobacter and Upper Gastrointestinal Research
- Vol. 26 (3) , 345-350
Open AccessAn Intraductal Papillary Mucinous Neoplasm–Like Lesion Manifesting as a Duodenal Polyp: A Rare Case Report
Intraductal papillary mucinous neoplasms (IPMNs) typically originate within the pancreatic ductal system. However, the occurrence of an IPMN–like mucinous neoplasm outside the pancreas, presenting as an isolated duodenal polyp, is extremely rare. An asymptomatic 64-year-old woman underwent routine screening endoscopy, which revealed a 25-mm Yamada type IV pedunculated polypoid lesion in the second portion of the duodenum. En bloc endoscopic mucosal resection was performed without procedural complications, although histological evaluation revealed focal involvement of the deep resection margin. Histopathological examination demonstrated a mucinous neoplasm confined within the duodenal submucosa with papillary architecture and low-grade dysplasia, which was designated as a duodenal IPMN–like lesion. Post-procedural CT showed no concurrent pancreatic involvement, and endoscopy at 6 months demonstrated a stable post-resection scar without local recurrence. Extended follow-up with dedicated pancreatic imaging is ongoing. This case report describes a particularly uncommon duodenal IPMN–like lesion presenting as a polyp. This case highlights the importance of careful histological evaluation and the inclusion of pancreaticobiliary-type neoplasms in the differential diagnosis of atypical periampullary lesions, along with long-term surveillance.
- Open Access
- 3 September 2026
- Published by Wiley in Alimentary Pharmacology & Therapeutics
Letter: P‐ CABs Versus PPIs for Gastroprotection During Antithrombotic Therapy: What Does Treatment Switching Tell us? Authors' Reply
- 3 September 2026
- Published by Wiley in Alimentary Pharmacology & Therapeutics
Open AccessLetter: P‐ CABs Versus PPIs for Gastroprotection During Antithrombotic Therapy: What Does Treatment Switching Tell us? Authors' Reply
- Open Access
- 13 July 2026
- Published by Wiley in Helicobacter
- Vol. 31 (4) , e70149
Evidence‐Based Guidelines for the Diagnosis and Treatment of Helicobacter pylori Infection in Korea: 2025 Revised Edition
Background/Aims: Since the 2020 Korean guidelines for Helicobacter pylori treatment, clarithromycin resistance rates have risen from 17.8% to 33.3%, dual‐priming oligonucleotide‐based polymerase chain reaction (DPO‐PCR)‐based tailored therapy has been adopted, and P‐CABs have become available. This fourth revision addresses these changes. Methods: Nine key questions were addressed through systematic reviews with meta‐analyses. Thirteen recommendations were evaluated via modified Delphi process involving 64 experts. Results: Twelve recommendations achieved first‐round consensus; one required revision and achieved 73.9% agreement. Key changes: (1) dual‐pillar strategy of tailored therapy and empirical quadruple therapy; (2) restricted use of empirical clarithromycin‐based triple therapy under specific conditions; (3) removal of sequential therapy; (4) P‐CABs as PPI alternatives; (5) expansion of eradication indications to include gastric cancer prevention in H. pylori gastritis and regression of hyperplastic polyps ≤ 10 mm; and (6) positioning of bismuth quadruple therapy as a conditionally recommended first‐line empirical option with preference for reservation as salvage therapy, and introduction of modified bismuth quadruple therapy (addition of bismuth to conventional regimens) as an additional first‐line empirical option. Conclusions: This fourth revised guideline provides updated, evidence‐based recommendations for the diagnosis and treatment of H. pylori infection, reflecting the rapidly changing antibiotic resistance landscape and the introduction of new diagnostic and therapeutic tools in Korea. These guidelines aim to assist clinicians, patients, policymakers, and medical educators in optimizing H. pylori management. They may differ from current medical insurance standards and will be revised further based on emerging evidence.
- 13 July 2026
- Published by Wiley in Helicobacter
- Vol. 31 (4) , e70149
Open AccessEvidence‐Based Guidelines for the Diagnosis and Treatment of Helicobacter pylori Infection in Korea: 2025 Revised Edition
Background/Aims: Since the 2020 Korean guidelines for Helicobacter pylori treatment, clarithromycin resistance rates have risen from 17.8% to 33.3%, dual‐priming oligonucleotide‐based polymerase chain reaction (DPO‐PCR)‐based tailored therapy has been adopted, and P‐CABs have become available. This fourth revision addresses these changes. Methods: Nine key questions were addressed through systematic reviews with meta‐analyses. Thirteen recommendations were evaluated via modified Delphi process involving 64 experts. Results: Twelve recommendations achieved first‐round consensus; one required revision and achieved 73.9% agreement. Key changes: (1) dual‐pillar strategy of tailored therapy and empirical quadruple therapy; (2) restricted use of empirical clarithromycin‐based triple therapy under specific conditions; (3) removal of sequential therapy; (4) P‐CABs as PPI alternatives; (5) expansion of eradication indications to include gastric cancer prevention in H. pylori gastritis and regression of hyperplastic polyps ≤ 10 mm; and (6) positioning of bismuth quadruple therapy as a conditionally recommended first‐line empirical option with preference for reservation as salvage therapy, and introduction of modified bismuth quadruple therapy (addition of bismuth to conventional regimens) as an additional first‐line empirical option. Conclusions: This fourth revised guideline provides updated, evidence‐based recommendations for the diagnosis and treatment of H. pylori infection, reflecting the rapidly changing antibiotic resistance landscape and the introduction of new diagnostic and therapeutic tools in Korea. These guidelines aim to assist clinicians, patients, policymakers, and medical educators in optimizing H. pylori management. They may differ from current medical insurance standards and will be revised further based on emerging evidence.
- Open Access
- 1 July 2026
- Published by Korean Association of Internal Medicine in The Korean Journal of Internal Medicine
- Vol. 41 (4) , 649-662
The 2020 disease burden and economic implications of digestive diseases in Korea: a nation-wide comprehensive study
Background/Aims: Digestive diseases are highly prevalent and contribute substantially to healthcare utilization and costs. However, national-level data on digestive diseases burden in Korea are limited. This study aimed to estimate the healthcare burden of digestive diseases in Korea via a national database analysis.Methods: We analyzed the 2020 National Patient Sample data from the Health Insurance Review and Assessment Service, covering the entire Korean population. Digestive diseases were grouped into seven categories. Medical utilization and expenditures were assessed using two criteria: the principal estimate (primary diagnosis only) and the extended estimate (primary plus first-listed secondary diagnosis).Results: Approximately 18.5 million individuals (39.2% of all patients) received care for digestive diseases, according to the principal estimate, and 30.1 million (63.8%) received care, according to the extended estimate. Corresponding medical exdigespenditures were $8.5 billion (11.6% of total national healthcare costs) based on the principal estimate and $14.4 billion (19.6%) based on the extended estimate. Although only 7.4% of patients were hospitalized, they accounted for 51.4% of the total expenditure for digestive diseases. Colorectal cancer incurred the highest inpatient costs. Gastroesophageal reflux disease was the most common and expensive diagnosis in outpatients. Intestinal infectious diseases were the leading causes of hospitalization and emergency department visits; foreign body ingestion was a key driver in pediatric emergency cases.Conclusions: Digestive diseases impose significant clinical and economic burdens in Korea. Their frequent occurrence as primary and comorbid diseases highlights the need for comprehensive healthcare strategies and informed policy planning.
- 1 July 2026
- Published by Korean Association of Internal Medicine in The Korean Journal of Internal Medicine
- Vol. 41 (4) , 649-662
Open AccessThe 2020 disease burden and economic implications of digestive diseases in Korea: a nation-wide comprehensive study
Background/Aims: Digestive diseases are highly prevalent and contribute substantially to healthcare utilization and costs. However, national-level data on digestive diseases burden in Korea are limited. This study aimed to estimate the healthcare burden of digestive diseases in Korea via a national database analysis.Methods: We analyzed the 2020 National Patient Sample data from the Health Insurance Review and Assessment Service, covering the entire Korean population. Digestive diseases were grouped into seven categories. Medical utilization and expenditures were assessed using two criteria: the principal estimate (primary diagnosis only) and the extended estimate (primary plus first-listed secondary diagnosis).Results: Approximately 18.5 million individuals (39.2% of all patients) received care for digestive diseases, according to the principal estimate, and 30.1 million (63.8%) received care, according to the extended estimate. Corresponding medical exdigespenditures were $8.5 billion (11.6% of total national healthcare costs) based on the principal estimate and $14.4 billion (19.6%) based on the extended estimate. Although only 7.4% of patients were hospitalized, they accounted for 51.4% of the total expenditure for digestive diseases. Colorectal cancer incurred the highest inpatient costs. Gastroesophageal reflux disease was the most common and expensive diagnosis in outpatients. Intestinal infectious diseases were the leading causes of hospitalization and emergency department visits; foreign body ingestion was a key driver in pediatric emergency cases.Conclusions: Digestive diseases impose significant clinical and economic burdens in Korea. Their frequent occurrence as primary and comorbid diseases highlights the need for comprehensive healthcare strategies and informed policy planning.
- 30 June 2026
- Published by Wiley in Alimentary Pharmacology & Therapeutics
- Vol. 64 (6) , 850-851
Letter: Interpreting P‐ CAB Superiority for Antithrombotic Gastroprotection Beyond Acid Suppression. Authors' Reply
- 30 June 2026
- Published by Wiley in Alimentary Pharmacology & Therapeutics
- Vol. 64 (6) , 850-851
Letter: Interpreting P‐ CAB Superiority for Antithrombotic Gastroprotection Beyond Acid Suppression. Authors' Reply
- Open Access
- 10 June 2026
- Published by Korean College of Helicobacter and Upper Gastrointestinal Research in The Korean Journal of Helicobacter and Upper Gastrointestinal Research
- Vol. 26 (2) , 164-188
Evidence-Based Guidelines for the Diagnosis and Treatment of Helicobacter pylori Infection in Korea: 2025 Revised Edition
Evidence-Based Guidelines for the Diagnosis and Treatment of Helicobacter pylori Infection in Korea: 2025 Revised Edition
- 10 June 2026
- Published by Korean College of Helicobacter and Upper Gastrointestinal Research in The Korean Journal of Helicobacter and Upper Gastrointestinal Research
- Vol. 26 (2) , 164-188
Open AccessEvidence-Based Guidelines for the Diagnosis and Treatment of Helicobacter pylori Infection in Korea: 2025 Revised Edition
Evidence-Based Guidelines for the Diagnosis and Treatment of Helicobacter pylori Infection in Korea: 2025 Revised Edition
- 1 June 2026
- Published by Wiley in Alimentary Pharmacology & Therapeutics
- Vol. 64 (4) , 529-530
Editorial: Prevention of Upper GI Bleeding in Users of Anti‐Thrombotic Drugs—P‐ CABs Versus PPIs . Authors' Reply
- 1 June 2026
- Published by Wiley in Alimentary Pharmacology & Therapeutics
- Vol. 64 (4) , 529-530
Editorial: Prevention of Upper GI Bleeding in Users of Anti‐Thrombotic Drugs—P‐ CABs Versus PPIs . Authors' Reply
- Top Cited PapersOpen Access
- 9 May 2026
- Published by Wiley in Alimentary Pharmacology & Therapeutics
- Vol. 64 (4) , 499-506
P‐ CAB vs. PPI for Upper Gastrointestinal Bleeding Prevention in Patients With Atherothrombotic Disease on Antithrombotic Therapy: A CDM Cohort Study
Background: Randomised trials have suggested the benefit of potassium‐competitive acid blockers (P‐CABs) is superior to proton pump inhibitors (PPIs) for ulcer recurrence in high‐risk aspirin users. However, real‐world comparative effectiveness across diverse antithrombotic regimens remains poorly defined. Objective: We evaluated P‐ CABs versus PPIs for preventing upper gastrointestinal ( GI ) bleeding in patients with acute atherothrombotic disease and using antithrombotic therapy. Design: This retrospective cohort study utilised hospital‐based Common Data Model data (2018–2024). Patients with acute cardiovascular or cerebrovascular disease receiving antithrombotic therapy who initiated a PPI or P‐CAB were included. Drug exposure was modelled as a time‐varying variable to mitigate immortal‐time bias. The primary outcome was upper GI bleeding, analysed via time‐dependent Cox regression adjusted for age, sex, comorbidities, and concomitant medications. Results: Among 2255 patients (PPI: 1726; P‐CAB: 529) in which 53 upper GI bleeding events occurred during a median follow‐up of 637 days. P‐CAB use was associated with a significantly lower risk of upper GI bleeding than PPIs (incidence rate 5.7 vs. 25.8 per 1000 person‐year; adjusted hazard ratio [HR] 0.22, 95% CI 0.06–0.75, p = 0.016). P‐CABs showed a profound reduction in moderate‐to‐severe upper GI bleeding (HR 0.11, 95% CI 0.02–0.60; p = 0.011). Notably, no bleeding events occurred in P‐CAB users with high antithrombotic burden (≥ 2 agents). Conclusions: In patients receiving antithrombotic therapy, P‐CABs are associated with a significantly lower risk of clinically significant GI bleeding compared to PPIs. These findings support P‐CABs as a potent acid‐suppressive strategy for gastroprotection in high‐risk populations.
- 9 May 2026
- Published by Wiley in Alimentary Pharmacology & Therapeutics
- Vol. 64 (4) , 499-506
Top Cited PapersOpen AccessP‐ CAB vs. PPI for Upper Gastrointestinal Bleeding Prevention in Patients With Atherothrombotic Disease on Antithrombotic Therapy: A CDM Cohort Study
Background: Randomised trials have suggested the benefit of potassium‐competitive acid blockers (P‐CABs) is superior to proton pump inhibitors (PPIs) for ulcer recurrence in high‐risk aspirin users. However, real‐world comparative effectiveness across diverse antithrombotic regimens remains poorly defined. Objective: We evaluated P‐ CABs versus PPIs for preventing upper gastrointestinal ( GI ) bleeding in patients with acute atherothrombotic disease and using antithrombotic therapy. Design: This retrospective cohort study utilised hospital‐based Common Data Model data (2018–2024). Patients with acute cardiovascular or cerebrovascular disease receiving antithrombotic therapy who initiated a PPI or P‐CAB were included. Drug exposure was modelled as a time‐varying variable to mitigate immortal‐time bias. The primary outcome was upper GI bleeding, analysed via time‐dependent Cox regression adjusted for age, sex, comorbidities, and concomitant medications. Results: Among 2255 patients (PPI: 1726; P‐CAB: 529) in which 53 upper GI bleeding events occurred during a median follow‐up of 637 days. P‐CAB use was associated with a significantly lower risk of upper GI bleeding than PPIs (incidence rate 5.7 vs. 25.8 per 1000 person‐year; adjusted hazard ratio [HR] 0.22, 95% CI 0.06–0.75, p = 0.016). P‐CABs showed a profound reduction in moderate‐to‐severe upper GI bleeding (HR 0.11, 95% CI 0.02–0.60; p = 0.011). Notably, no bleeding events occurred in P‐CAB users with high antithrombotic burden (≥ 2 agents). Conclusions: In patients receiving antithrombotic therapy, P‐CABs are associated with a significantly lower risk of clinically significant GI bleeding compared to PPIs. These findings support P‐CABs as a potent acid‐suppressive strategy for gastroprotection in high‐risk populations.
- Top Cited PapersOpen Access
- 10 March 2026
- Published by Korean College of Helicobacter and Upper Gastrointestinal Research in The Korean Journal of Helicobacter and Upper Gastrointestinal Research
- Vol. 26 (1) , 23-36
Treatment of Helicobacter pylori Infection in Korea: An Evidence-Based Analysis of the Upcoming 2025 Guideline
Treatment of Helicobacter pylori Infection in Korea: An Evidence-Based Analysis of the Upcoming 2025 Guideline
- 10 March 2026
- Published by Korean College of Helicobacter and Upper Gastrointestinal Research in The Korean Journal of Helicobacter and Upper Gastrointestinal Research
- Vol. 26 (1) , 23-36
Top Cited PapersOpen AccessTreatment of Helicobacter pylori Infection in Korea: An Evidence-Based Analysis of the Upcoming 2025 Guideline
Treatment of Helicobacter pylori Infection in Korea: An Evidence-Based Analysis of the Upcoming 2025 Guideline